

Lynne V Abruzzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/532943/publications.pdf>

Version: 2024-02-01

27
papers

1,170
citations

933447

10
h-index

677142

22
g-index

28
all docs

28
docs citations

28
times ranked

1845
citing authors

#	ARTICLE	IF	CITATIONS
1	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	7.1	498
2	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, 11589.	12.8	285
3	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	7.0	122
4	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	1.6	71
5	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 17.	17.0	31
6	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 688-698.	1.4	26
7	Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. <i>Lancet Oncology</i> , The, 2019, 20, 1576-1586.	10.7	26
8	Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. <i>Haematologica</i> , 2018, 103, 2069-2078.	3.5	25
9	Unsupervised machine learning and prognostic factors of survival in chronic lymphocytic leukemia. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1019-1027.	4.4	18
10	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	1.4	12
11	Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. <i>Cancer Genetics</i> , 2015, 208, 571-574.	0.4	9
12	CytoGPS: a web-enabled karyotype analysis tool for cytogenetics. <i>Bioinformatics</i> , 2019, 35, 5365-5366.	4.1	8
13	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , 2016, 128, 55-55.	1.4	8
14	Electronic Health Records and Genomics. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 1-17.	2.8	8
15	Thirty biologically interpretable clusters of transcription factors distinguish cancer type. <i>BMC Genomics</i> , 2018, 19, 738.	2.8	6
16	Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing. <i>Bioinformatics</i> , 2019, 35, 2924-2931.	4.1	3
17	Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. <i>Leukemia</i> , 2021, 35, 3406-3420.	7.2	3
18	RCytoGPS: an R package for reading and visualizing cytogenetics data. <i>Bioinformatics</i> , 2021, 37, 4589-4590.	4.1	3

#	ARTICLE	IF	CITATIONS
19	CytoGPS: A large-scale karyotype analysis of CML data. <i>Cancer Genetics</i> , 2020, 248-249, 34-38.	0.4	2
20	Pattern recognition in lymphoid malignancies using CytoGPS and Mercator. <i>BMC Bioinformatics</i> , 2021, 22, 100.	2.6	2
21	Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL. <i>Journal of Clinical Oncology</i> , 2022, 40, 7540-7540.	1.6	2
22	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Blood</i> , 2020, 136, 2-3.	1.4	1
23	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 22-23.	1.4	1
24	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2021, 35, 3287-3290.	7.2	0
25	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. <i>Blood</i> , 2016, 128, 3198-3198.	1.4	0
26	Aberrant Methylation and Decreased Expression of NRIP1 in IGHV-Unmutated CLL. <i>Blood</i> , 2016, 128, 1527-1527.	1.4	0
27	Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status. <i>Blood</i> , 2021, 138, 1563-1563.	1.4	0